File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of acute cortical infarct with intravenous glycerol: A double- blind, placebo-controlled randomized trial

TitleTreatment of acute cortical infarct with intravenous glycerol: A double- blind, placebo-controlled randomized trial
Authors
Issue Date1993
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://stroke.ahajournals.org
Citation
Stroke, 1993, v. 24 n. 8, p. 1119-1124 How to Cite?
AbstractBackground and Purpose: This clinical trial investigates the effectiveness of intravenous glycerol therapy in patients with acute cortical infarction in whom intracerebral hemorrhage was rigorously excluded. Methods: Within 48 hours of symptoms from their first ischemic stroke, 113 hospital inpatients were randomized into the trial, provided that hemorrhage was excluded by computed tomography and informed consent was obtained. Patients were stratified into alert, semicoma, and coma groups using the Glasgow Coma Scale. Treatment was allocated according to a double-blind, randomized protocol; 56 patients received 500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days, and 57 patients received corresponding placebo treatment with saline. Using a variety of objective scoring systems, patient follow-up was up to 6 months. Results: Corresponding measures of outcome in the glycerol and placebo groups were similar. At 6 months, respective mortality rates were 17 of 56 and 16 of 57, and mean±SD improvements in scores were 9.98±14.40 vs 10.51±12.68 (long-term), 1.12±7.20 vs 1.57±6.30 (prognostic), -1.94±5.53 vs -2.06±5.34 (Glasgow Coma Scale), and 21.72±23.40 vs 11.94±18.10 (Barthel Index rating in survivors). Hemolysis (generally subclinical) was the only adverse effect. Conclusions: There was no clinically or statistically significant difference in outcome between the groups; a trend toward greater functional recovery among survivors was evident after treatment with glycerol.
Persistent Identifierhttp://hdl.handle.net/10722/161968
ISSN
2015 Impact Factor: 5.787
2015 SCImago Journal Rankings: 3.671
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYu, YLen_US
dc.contributor.authorKumana, CRen_US
dc.contributor.authorLauder, IJen_US
dc.contributor.authorCheung, YKen_US
dc.contributor.authorChan, FLen_US
dc.contributor.authorKou, Men_US
dc.contributor.authorFong, KYen_US
dc.contributor.authorCheung, RTFen_US
dc.contributor.authorChang, CMen_US
dc.date.accessioned2012-09-05T05:16:22Z-
dc.date.available2012-09-05T05:16:22Z-
dc.date.issued1993en_US
dc.identifier.citationStroke, 1993, v. 24 n. 8, p. 1119-1124en_US
dc.identifier.issn0039-2499en_US
dc.identifier.urihttp://hdl.handle.net/10722/161968-
dc.description.abstractBackground and Purpose: This clinical trial investigates the effectiveness of intravenous glycerol therapy in patients with acute cortical infarction in whom intracerebral hemorrhage was rigorously excluded. Methods: Within 48 hours of symptoms from their first ischemic stroke, 113 hospital inpatients were randomized into the trial, provided that hemorrhage was excluded by computed tomography and informed consent was obtained. Patients were stratified into alert, semicoma, and coma groups using the Glasgow Coma Scale. Treatment was allocated according to a double-blind, randomized protocol; 56 patients received 500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days, and 57 patients received corresponding placebo treatment with saline. Using a variety of objective scoring systems, patient follow-up was up to 6 months. Results: Corresponding measures of outcome in the glycerol and placebo groups were similar. At 6 months, respective mortality rates were 17 of 56 and 16 of 57, and mean±SD improvements in scores were 9.98±14.40 vs 10.51±12.68 (long-term), 1.12±7.20 vs 1.57±6.30 (prognostic), -1.94±5.53 vs -2.06±5.34 (Glasgow Coma Scale), and 21.72±23.40 vs 11.94±18.10 (Barthel Index rating in survivors). Hemolysis (generally subclinical) was the only adverse effect. Conclusions: There was no clinically or statistically significant difference in outcome between the groups; a trend toward greater functional recovery among survivors was evident after treatment with glycerol.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://stroke.ahajournals.orgen_US
dc.relation.ispartofStrokeen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCerebral Cortexen_US
dc.subject.meshCerebral Infarction - Blood - Drug Therapy - Mortalityen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycerol - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHemolysisen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPlacebosen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleTreatment of acute cortical infarct with intravenous glycerol: A double- blind, placebo-controlled randomized trialen_US
dc.typeArticleen_US
dc.identifier.emailCheung, RTF:rtcheung@hku.hken_US
dc.identifier.authorityCheung, RTF=rp00434en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1161/01.STR.24.8.1119-
dc.identifier.pmid8342183-
dc.identifier.scopuseid_2-s2.0-0027197638en_US
dc.identifier.volume24en_US
dc.identifier.issue8en_US
dc.identifier.spage1119en_US
dc.identifier.epage1124en_US
dc.identifier.isiWOS:A1993LP59000002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYu, YL=8094845300en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US
dc.identifier.scopusauthoridLauder, IJ=35564928000en_US
dc.identifier.scopusauthoridCheung, YK=7202111404en_US
dc.identifier.scopusauthoridChan, FL=7202586444en_US
dc.identifier.scopusauthoridKou, M=7004545950en_US
dc.identifier.scopusauthoridFong, KY=8913866800en_US
dc.identifier.scopusauthoridCheung, RTF=7202397498en_US
dc.identifier.scopusauthoridChang, CM=7407031960en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats